<DOC>
	<DOCNO>NCT02147587</DOCNO>
	<brief_summary>This study evaluate immune response follow administration zoster vaccine subject rheumatoid arthritis receive background methotrexate initiate 5 mg twice daily tofacitinib placebo tofacitinib 2 3 week follow vaccination .</brief_summary>
	<brief_title>A Study Assess Immune Response Following Zoster Vaccination Subjects With Rheumatoid Arthritis Receiving Tofacitinib Placebo With Background Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects must moderate severe rheumatoid arthritis inadequately control methotrexate define American College Rheumatology ( ACR ) classification criterion Rheumatoid arthritis , painful swollen joint count Creactive protein ( CRP ) . Screening CRP &gt; 3 mg/L CDAI score &gt; 10 screen baseline vaccination . Subjects must active disease screen baseline . Must least 50 year age old . History receive varicellazoster virus vaccine Receipt vaccine within 6 week first dose study treatment . Subjects current infection history infection . History recurrent ( one episode ) herpes zoster disseminate ( single episode ) herpes zoster disseminate ( single episode ) herpes simplex .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>